A prospective study of postmenopausal hormone use and ovarian cancer risk

British Journal of Cancer

Volumn 96, Issue 1, 2007, Pages 151-156

  Danforth, K N ^a,d   Tworoger, S S ^a,b   Hecht, J L ^c   Rosner, B A ^a,b   Colditz, G A ^a,b   Hankinson, S E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d CHANNING LABORATORY   (United States)

Author keywords

Epidemiology; Hormone; Ovarian cancer; Postmenopausal

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; CANCER RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NURSE; OBSERVATIONAL STUDY; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

COHORT STUDIES; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; POSTMENOPAUSE; PROGESTINS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS;

EID: 33846236521     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603527     Document Type: Article

References (40)

1. American Cancer Society (2006) Cancer Facts & Figures. American Cancer Society Inc: Atlanta
2. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290: 1739-1748
3. Bakken K, Alsaker E, Eggen AE, Lund E (2004) Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 112: 130-134
4. Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427
5. Bertone ER, Rosner BA, Hunter DJ, Stampfer MJ, Speizer FE, Colditz GA, Willett WC, Hankinson SE (2002) Dietary fat intake and ovarian cancer in a cohort of US women. Am J Epidemiol 156: 22-31
6. Bosetti C, Negri E, Franceschi S, Trichopoulos D, Beral V, La Vecchia C (2001) Relationship between postmenopausal hormone replacement therapy and ovarian cancer. [comment]. JAMA 285: 3089; discussion 3090
7. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589-1593
8. Colditz GA, Stampfer MJ, Willett WC, Stason WB, Rosner B, Hennekens CH, Speizer FE (1987) Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol 126: 319-325
9. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350: 1047-1059
10. Coughlin SS, Giustozzi A, Smith SJ, Lee NC (2000) A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 53: 367-375
11. Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71: 717-721
12. Cunat S, Hoffmann P, Pujol P (2004) Estrogens and epithelial ovarian cancer. Gynecol Oncol 94: 25-32
13. Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE, Hankinson SE (2002) Obesity, weight gain, and ovarian cancer. Obstet Gynecol 100: 288-296
14. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA (2005) Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev, CD004143
15. Folsom AR, Anderson JP, Ross JA (2004) Estrogen replacement therapy and ovarian cancer. Epidemiology 15: 100-104
16. Fraser IS, Jansen RPS, Lobo RA, Whitehead MI (1998) Estrogens and Progestogens in Clinical Practice. Churchill Livingstone: London, New York
17. Garg PP, Kerlikowske K, Subak L, Grady D (1998) Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92: 472-479
18. Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E, Bock JE, Blaakaer J (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164: 2253-2259
19. Ho SM (2003) Estrogen, Progesterone and Epithelial Ovarian Cancer. Reprod Biol Endocrinol 1: 73
20. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, International Agency for Research on Cancer, World Health Organization (1999) Hormonal Contraception and Post-Menopausal Hormonal Therapy. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; vol. 72. IARC; Distributed by IARC Press and the World Health Organization Distribution and Sales: Lyon, France, Geneva
21. Kaufman DW, Kelly JP, Welch WR, Rosenberg L, Stolley PD, Warshauer ME, Lewis J, Woodruff J, Shapiro S (1989) Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 130: 1142-1151
22. Kumar V, Cotran RS, Robbins SL (1997) Basic Pathology 6th edn, W.B. Saunders: Philadelphia
23. Lacey Jr JV, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, Hartge P (2006) Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 98: 1397-1405
24. Lacey Jr JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. [comment][erratum appears in JAMA 2002 Nov 27; 288(20): 2544]. JAMA 288: 334-341
25. Mills PK, Riordan DG, Cress RD (2004) Epithelial ovarian cancer risk by invasiveness and cell type in the Central Valley of California. Gynecol Oncol 95: 215-225
26. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Berchuck A (2005) Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 193: 76-82
27. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288: 872-881
28. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH (2004) Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 82: 186-195
29. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR (2002) Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94: 497-504
30. Riman T, Nilsson S, Persson IR (2004) Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 83: 783-795
31. Risch HA (1996) Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 63: 254-257
32. Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90: 1774-1786
33. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. [comment]. JAMA 285: 1460-1465
34. Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M, Whitaker RS, Isner P, Berchuck A, Dodge RK, Hughes CL (2002) Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 94: 50-60
35. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, Dodge R, Hughes CL (1998) Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 5: 271-276
36. Sit AS, Modugno F, Weissfeld JL, Berga SL, Ness RB (2002) Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 86: 118-123
37. USPSTF (2005) Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the US. Preventive Services Task Force. Ann Intern Med 142: 855-860
38. Weiss NS, Hill DA (1996) Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Maturitas 23: 235-239
39. Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE, Liff JM, Daling JR (1982) Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 68: 95-98
40. Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136: 1184-1203